Cardarine (10 mg/ml) – 30 ml Liquid Solution

Cardarine (GW501516) – a premium-grade liquid research solution designed for those seeking advanced metabolic support and endurance enhancement. This research chemical is one of the most widely studied PPARδ receptor agonists in the research community. It’s a go-to compound for researchers exploring the boundaries of fat metabolism, energy utilization, and physical performance.

Cardarine (GW501516)

Product Summary

• Compound: Cardarine (GW501516)
• Concentration: 10 mg/ml
• Volume: 30 ml dropper bottle
• Form: Liquid solution for research purposes
• Purity: >99% pharmaceutical-grade
• CAS Number: 317318-70-0
• Molecular Formula: C₂₁H₁₈F₃NO₃S₂

What is Cardarine (GW501516)?

Cardarine (GW501516) – 10 mg/ml Liquid Solution: Comprehensive Overview

Cardarine (GW501516)

1. Compound Profile

• Chemical Name: Cardarine (GW501516)
• Concentration: 10 mg/ml
• Volume: 30 mL (UV-resistant dropper bottle)
• Purity: >99% pharmaceutical-grade
• Molecular Formula: C21H18F3NO3S2C21​H18​F3​NO3​S2​
• CAS Number: 317318-70-0

---

2. Mechanism of Action

Cardarine is a PPARδ receptor agonist that operates through:

• Fat Oxidation: Activates PPARδ pathways to enhance fatty acid metabolism.
• Mitochondrial Efficiency: Boosts mitochondrial biogenesis in skeletal muscle.
• Non-Hormonal Action: Unlike SARMs/steroids, it avoids androgen receptor binding, eliminating hormonal side effects.

---

3. Key Research Applications

Metabolic & Performance Benefits

• Fat Loss: Promotes preferential fat utilization over glucose, ideal for studies on obesity/metabolic syndrome.
• Endurance Enhancement: Increases Type I (slow-twitch) muscle fiber activity, improving stamina in animal models.
• Muscle Preservation: Reduces catabolism during caloric restriction (e.g., studies on muscle atrophy).
• Insulin Sensitivity: Shown to improve glucose uptake in preclinical trials.

Safety Profile

• No Testosterone Suppression: No observed HPTA axis disruption in research models.
• Non-Stimulant: Avoids cardiovascular strain associated with caffeine/amphetamines.
• Half-Life: 16–24 hours, enabling once-daily dosing in experimental protocols.

---

4. Product Advantages

Feature	Benefit
Pharma-Grade Carrier	Optimizes solubility and bioavailability for in vitro studies
Tamper-Proof Packaging	UV-resistant glass ensures compound stability
Precision Dosing	Graduated dropper allows ±0.1 mL accuracy (1 mg increments)
Global Compliance	Manufactured under ISO 9001 standards

---

5. Experimental Protocol Guidelines

• Dosage Range: 10–20 mg/day (1–2 mL) in rodent models
• Administration: Oral or subcutaneous (carrier solution is ethanol/PEG-400 based)
• Stacking: Often paired with $SR9009$ (Rev-ErbA agonist) for synergistic fat oxidation effects
• Storage: Stable at 15–25°C; avoid freezing

---

6. Ethical & Legal Considerations

• Research-Only Use: Not approved for human/veterinary applications.
• Institutional Compliance: Requires verification of lab credentials for purchase.
• Regulatory Status: Banned by WADA (2019) but legal for non-clinical research.

---

7. Limitations & Research Gaps

• Cardiovascular Risks: Early-stage trials (2007) reported tumorigenic potential in rodents at high doses (>10× human equivalent).
• Long-Term Data: No multi-year studies on chronic exposure.
• Species Variability: Effects in primates show weaker PPARδ activation than rodents.

---

8. Future Research Directions

1. Cancer Metabolism: Explore PPARδ’s role in tumor microenvironments.
2. Aging Studies: Mitochondrial enhancement for age-related muscle wasting.
3. Neuroprotection: Potential PPARδ-mediated effects on CNS lipid metabolism.